+1 877 705 1914• 24 / 7
HIPAA Compliant
ISO 27001 Certified

Actively Recruiting

Phase 2
Age: 6Months - 23Months
All Genders
ID07660835

Open-Label Study of Nemolizumab in Children Aged 6 to 23 Months with Moderate-to-Severe Atopic Dermatitis Not Controlled by Topical Therapy

Led by Galderma R&D · Updated on 2026-08-14

35

Participants Needed

1

Research Sites

N/A

Total Duration

AI-Summary

What This Trial Is About

Researchers are evaluating the pharmacokinetics and safety of nemolizumab in young children aged 6 to 23 months who have moderate-to-severe atopic dermatitis that is not well controlled with topical treatments. This Phase 2 study aims to understand how the medicine behaves in the body and assess its safety in this pediatric population. Participants will first receive a high loading dose of nemolizumab by subcutaneous injection at the start of the study. Following this, they will receive a lower dose every 4 weeks for a total treatment period of 52 weeks, with the last dose given at week 48. After completing treatment, there is an 8-week safety follow-up period. Participants who stop treatment early will be followed for 12 weeks after their last dose. During the study, participants will have blood samples taken before doses at weeks 4, 16, 32, and 52 to measure drug levels and other pharmacokinetic parameters. Safety is monitored throughout treatment and follow-up by tracking adverse events. Parents or caregivers will also report on the childs symptoms and skin condition. The total participation time for each child is approximately 60 weeks from baseline.

CONDITIONS

Brief Title

Pharmacokinetics, Safety and Efficacy of Nemolizumab in Participants Aged 6 to 23 Months With Moderate-to Severe Atopic Dermatitis

Research Team

G

Galderma Research and Development

Not the Right Trial for You?

Explore thousands of other clinical trials that might be a better match.
Sign up to get personalized trial recommendations delivered to your inbox.

Already have an account? Log in here